Pharma BD Deal Intelligence

Pfizer Inc. / Seagen Inc.

2023 · Acquisition/Merger · $43.0B · Complete

Announcement Sentiment

Strongly positive

Outcome Score

Worked — the deal delivered on its rationale.

Pfizer acquired Seagen for approximately $43 billion ($229 per share in cash), gaining Seagen's world-leading antibody-drug conjugate (ADC) technology platform, four marketed oncology medicines (Adcetris, Padcev, Tivdak, Tukysa), and eleven pipeline candidates. The deal doubled Pfizer's oncology pipeline and positioned the company to generate over $10 billion in risk-adjusted oncology revenues by 2030.

Key facts

Announced Mar 13, 2023
Closed Dec 14, 2023
Deal value $43.0B
Deal type Acquisition/Merger
Therapeutic area Oncology
Indications Hodgkin Lymphoma, Urothelial Cancer, Cervical Cancer, HER2-Positive Breast Cancer, Colorectal Cancer
Key assets Adcetris (brentuximab vedotin), Padcev (enfortumab vedotin), Tivdak (tisotumab vedotin), Tukysa (tucatinib), ADC technology platform, 11 pipeline NMEs
Mechanism Antibody-drug conjugate (ADC), Anti-CD30 ADC, Anti-Nectin-4 ADC, Anti-Tissue Factor ADC, HER2-targeted small molecule kinase inhibitor

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals